Suchergebnisse - "Thompson, John L.P."

PubPharm (8)

1

Mitochondrial disease patient motivations and barriers to participate in clinical trials

enthalten in: PloS one | 2018

von Zolkipli-Cunningham, Z. | Xiao, R. | Stoddart, A. | +8

2

Tenecteplase versus alteplase in stroke thrombolysis : An individual patient data meta-analysis of randomized controlled trials

enthalten in: International journal of stroke : official journal of the International Stroke Society | 2016

von Huang, X. | MacIsaac, R. | Thompson, J. | +8

3

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm : Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy

enthalten in: Circulation. Heart failure | 2015

von Homma, S. | Thompson, J. | Qian, M. | +118

4

Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial

enthalten in: Cerebrovascular diseases (Basel, Switzerland) | 2014

von Pullicino, P. | Qian, M. | Sacco, R. | +115

5

Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm : a subgroup analysis of WARCEF, a randomized controlled trial

enthalten in: Circulation. Heart failure | 2013

von Homma, S. | Thompson, J. | Sanford, A. | +18

6

Stroke in heart failure in sinus rhythm : the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial

enthalten in: Cerebrovascular diseases (Basel, Switzerland) | 2013

von Pullicino, P. | Thompson, J. | Sacco, R. | +16

7

Warfarin and aspirin in patients with heart failure and sinus rhythm

enthalten in: The New England journal of medicine | 2012

von Homma, S. | Thompson, J. | Pullicino, P. | +122

CommentIn: N Engl J Med. 2012 May 17;366(20):1936-8. - PMID 22551103

8

Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke : an efficient, dose-adaptive, seamless phase II/III design

enthalten in: Clinical trials (London, England) | 2011

von Levin, B. | Thompson, J. | Chakraborty, B. | +3

1
[1]